Dacomitinib

Contact us
TargetMol
Product Code: TAR-T2483
Supplier: TargetMol
CodeSizePrice
TAR-T2483-1mg1mg£96.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2483-2mg2mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2483-1mL1 mL * 10 mM (in DMSO)£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2483-5mg5mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2483-10mg10mg£174.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2483-25mg25mg£222.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2483-50mg50mg£273.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2483-100mg100mg£374.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2483-200mg200mg£446.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2483-500mg500mg£688.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1
❮❯

Documents

Further Information

Bioactivity:
Dacomitinib(PF299804; PF-00299804) is a highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with IC50 of 6, 45.7 and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.
CAS:
1110813-31-4
Formula:
C24H25ClFN5O2
Molecular Weight:
469.95
Pathway:
Tyrosine Kinase/Adaptors; Apoptosis; JAK/STAT signaling; Angiogenesis
Purity:
0.9934
SMILES:
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=CCN1CCCCC1
Target:
Apoptosis; EGFR

References

1. Engelman JA, et al, Cancer Res, 2007, 67(24), 11924-11932. 2. Gonzales AJ, et al, Mol Cancer Ther, 2008, 7(7), 1880-1889. 3. Nam HJ, et al, Mol Cancer Ther, 2012, 11(2), 439-451. 4. Kalous O, et al, Mol Cancer Ther, 2012, Jul 3.